Enterprise Value
2.386B
Cash
436.6M
Avg Qtr Burn
-59.98M
Short % of Float
14.57%
Insider Ownership
2.21%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date | |
---|---|---|---|
Mirdametinib Details NF1-associated Plexiform Neurofibromas, Cancer | No event data in pipeline | | |
OGSIVEO (Nirogacestat) (gamma secretase inhibitor) Details Desmoid tumors | Approved Quarterly sales | ||
Nirogacestat Details Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors | Phase 2 Data readout | ||
Nirogacestat combo w/ belantamab Details Multiple myeloma, Cancer | Phase 1/2 Data readout | ||
Brimarafenib (BGB-3245) + mirdametinib Details Solid tumor/s, Cancer | Phase 1/2 Data readout | ||
Mirdametinib + lifirafenib Details Cancer, Solid tumor/s | Phase 1/2 Data readout | ||
Mirdametinib (MEK inhibitor) Details Cancer, Glioma | Phase 1/2 Data readout | ||
Mirdametinib + fulvestrant (Faslodex) Details Breast cancer, Cancer | Phase 1/2 Update | ||
Nirogacestat + linvoseltamab Details Cancer, Multiple myeloma | Phase 1b Data readout | ||
Brimarafenib (BGB-3245) + panitumumab Details Cancer, Colorectal cancer , Pancreatic cancer | Phase 1b Data readout | ||
Nirogacestat + teclistamab Details Multiple myeloma, Cancer | Phase 1b Data readout | ||
Brimarafenib (BGB-3245) Details Solid tumor/s, Cancer | Phase 1b Data readout | ||
SW-682 [pan-TEAD inhibitor] Details Cancer, Solid tumor/s | Phase 1a Initiation |